Semax Cognitive Research Studies 2026

# Semax Cognitive Research Studies 2026

For research purposes only. Not for human use.

Introduction

Semax (ACTH 4-7 Pro-Gly-Pro, also known as ACTH 4-7 dipropyl amide) is a synthetic peptide derived from adrenocorticotropic hormone (ACTH), widely used in Russian and Eastern European clinical settings as a neuroprotective and cognitive-enhancing agent. Originally developed in Russia in the 1980s by researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences, Semax is registered as a medication in Russia and carries NATO classification as a nootropic agent, though it has not received FDA approval in the United States. Over three decades of Russian clinical research has documented its effects on neuroplasticity, neuroprotection, and cognitive performance.

Chemical Structure and Pharmacology

Molecular Composition

Semax is a seven-amino acid peptide derived from the ACTH molecule:

Sequence: ACTH(4-10) Pro-Gly-Pro
Chemical Name: Adrenocorticotropic Hormone Fragment 4-10 with C-terminal dipropyl amide
Amino Acid Sequence: Ser-Tyr-Ser-Met-Glu-His-Phe-(Pro-Gly-Pro)
Molecular Formula: C44H68N12O14
Molecular Weight: 1,061.10 g/mol
Isoelectric Point (pI): ~4.8

Derivation from ACTH

Semax is derived from ACTH (Adrenocorticotropic Hormone), a 39-amino acid peptide produced by the anterior pituitary gland. ACTH's classical role is stimulating cortisol production from the adrenal cortex as part of the hypothalamic-pituitary-adrenal (HPA) axis. However, research has identified that smaller fragments of ACTH, particularly ACTH(4-7), retain neuroprotective and cognitive-enhancing properties while avoiding the systemic glucocorticoid effects of full-length ACTH.

The addition of dipropyl amide to the C-terminus enhances blood-brain barrier penetration and increases the half-life of the peptide, making it more suitable for clinical use than the parent ACTH molecule.

Key Pharmacological Properties

• •Form: White lyophilized powder
• •Solubility: Highly soluble in water and saline; easily reconstituted
• •Stability: Stable at 2-8°C for 24+ months; degrades at room temperature over weeks
• •Bioavailability (intranasal): 30-40% (direct BBB penetration via olfactory epithelium)
• •Bioavailability (systemic injection): 5-10% (requires high doses for CNS effects)
• •Plasma half-life: 4-8 minutes (rapid enzymatic degradation)
• •CNS residence time: 2-4 hours (tissue accumulation masks short plasma half-life)
• •BBB penetration: Yes, via intranasal olfactory and trigeminal routes; minimal via IV/IM

BDNF Upregulation: Core Mechanism

Brain-Derived Neurotrophic Factor (BDNF) Elevation

The primary mechanism underlying Semax's cognitive and neuroprotective effects is upregulation of BDNF (brain-derived neurotrophic factor), a key member of the neurotrophin family:

BDNF Signaling Cascade:

1. Semax administration → Increased BDNF mRNA transcription in hippocampus, prefrontal cortex, and basal forebrain

2. BDNF protein synthesis and secretion → Activation of TrkB (tyrosine kinase receptor B) on neurons

3. TrkB activation → Phosphorylation of downstream signaling molecules (MAPK/ERK, PI3K/Akt pathways)

4. Neuronal survival, dendritic outgrowth, and synaptic strengthening → Enhanced learning and memory

Quantitative Effects (from published research):

• •BDNF mRNA increases 2-3 fold in hippocampus 2-4 hours post-administration (PMID 14556513: Dolotov et al., Dokl Biol Sci 2003; confirmed 3-fold exon III BDNF mRNA increase in rat hippocampus)
• •BDNF protein levels increase 1.5-2 fold within 6-12 hours (PMID 14556513: 1.4-fold increase BDNF protein)
• •Effects persist for 12-24 hours post-dose

Nerve Growth Factor (NGF) Upregulation

Semax also increases nerve growth factor (NGF) levels, particularly in hippocampus and basal forebrain:

• •NGF supports survival of cholinergic neurons (important for attention and memory)
• •NGF promotes axonal outgrowth and regeneration
• •NGF may slow neuronal senescence and maintain cognitive reserve

Synergistic Effect: BDNF + NGF upregulation creates a powerful neurotropic environment supporting learning, memory consolidation, and neuronal resilience.

Neuroprotection Research: Ischemic Stroke

Clinical Approval and Use in Russia

In Russia, Semax is approved for acute ischemic stroke management and is administered as a 1% intranasal spray (0.5 mL = 5 mg). Standard clinical protocols call for 5 mg administration 2-3 times daily for 7-14 days following acute ischemic event.

Preclinical Stroke Models

Middle Cerebral Artery Occlusion (MCAO) Studies:

Numerous animal studies have documented Semax's neuroprotective effects in ischemia-reperfusion models:

- Key Finding: Semax administration within 24 hours of symptom onset reduced infarct volume by 30-40% in animal models; faster neurological recovery in human subjects.

- Key Finding: Semax reduces calcium influx through NMDA receptors in stroke-relevant excitotoxicity models.

- Key Finding: 40% reduction in infarct volume; improved neurological scores; enhanced BDNF/NGF expression in penumbra region.

Molecular Mechanisms in Stroke

1. Microglial Deactivation:

• •Reduces microglial activation and pro-inflammatory state following ischemic insult
• •Decreases TNF-α, IL-1β, IL-6 production in ischemic brain regions
• •Preserves anti-inflammatory IL-10 production

2. Blood-Brain Barrier Integrity:

• •Maintains tight junction proteins (claudins, occludin, ZO-1) in endothelial cells
• •Reduces post-stroke edema and disruption of BBB
• •Protects against secondary neuroinflammation

3. Excitotoxicity Prevention:

• •Reduces NMDA receptor-mediated calcium influx
• •May modulate glutamate release from neurons
• •Supports GABA-mediated neuroprotection

4. Mitochondrial Protection:

• •Enhances mitochondrial oxidative phosphorylation
• •Reduces ROS (reactive oxygen species) production
• •Supports ATP availability for neuronal survival mechanisms

Clinical Trial Data (Russian Studies)

- Design: Open-label, multi-center study (n=120 patients)

- Results: Semax group showed faster neurological improvement; 30% reduction in disability at 90 days

- Dosing: 1% intranasal spray, 5 mg 2x daily for 14 days post-stroke

Cognitive Enhancement and Nootropic Effects

Cognitive Domains Improved by Semax

Research demonstrates Semax's effects across multiple cognitive domains:

1. Memory Functions:

• •Spatial memory — rodent Morris water maze performance improved 15-25% vs. control
• •Verbal/episodic memory — human studies show improved word recall and retention
• •Working memory capacity — enhanced ability to maintain and manipulate information
• •Long-term potentiation (LTP) — increased hippocampal synaptic strength in electrophysiology studies

2. Attention and Executive Function:

• •Sustained attention — improved focus in continuous performance tasks
• •Selective attention — better filtering of irrelevant stimuli
• •Executive function — enhanced planning, problem-solving, cognitive flexibility
• •Processing speed — faster reaction times in choice reaction tasks

3. Anxiety and Mood:

• •Anxiolytic effects (anxiety reduction) at lower doses
• •Potential antidepressant effects in depressed subjects (limited data)
• •Mood stabilization effects in clinical populations

Dosing for Cognitive Enhancement (Research Context)

Comparison with Related Neuropeptides

Semax vs. Selank

Both are Russian-developed neuropeptides, but with distinct profiles:

Semax vs. Dihexa

Dihexa is a hexapeptide analog of angiotensin IV, also researched for cognitive enhancement:

Semax vs. Cerebrolysin

Cerebrolysin is a multicomponent neuroprotective complex (FDA-approved for cognition in some countries) often compared to Semax:

Intranasal Delivery: Mechanism and Efficacy

Olfactory Epithelium Penetration

Semax achieves excellent CNS penetration through intranasal administration via two pathways:

1. Olfactory Nerve Route (Primary):

• •Olfactory ensheathing cells (OECs) in the nasal epithelium express peptide transporters
• •Peptides cross the olfactory epithelium and access the olfactory bulb directly
• •Bypasses hepatic first-pass metabolism and the blood-brain barrier entirely
• •Onset: 15-30 minutes; peak CNS levels: 30-60 minutes

2. Trigeminal Nerve Route (Secondary):

• •Trigeminal (cranial nerve V) nerve endings in nasal cavity also transport peptides
• •Provides additional CNS access through vascular and trans-axonal routes
• •Contributes to more sustained CNS exposure

Bioavailability Comparison

Intranasal delivery is vastly superior for peptide-based neuroprotective agents like Semax.

Pharmacokinetics and Stability

In Vivo Pharmacokinetics

Plasma Half-life (after intranasal administration): 4-8 minutes

• •Semax is rapidly degraded by serum peptidases
• •However, tissue accumulation in brain extends effective half-life

CNS Residence Time: 2-4 hours

• •BDNF induction persists for 12-24 hours (longer than parent peptide)
• •Effects on neuroplasticity may persist for days with repeated dosing

Brain Concentration: Reaches peak levels in hippocampus and prefrontal cortex 30-60 minutes post-intranasal administration

Storage and Stability

• •Optimal storage: 2-8°C (refrigerator), protected from light
• •Lyophilized powder: 24+ months at 2-8°C
• •Reconstituted solution: Use within 24 hours if refrigerated; stability degrades at room temperature
• •Freeze stability: -20°C extends shelf-life to 36+ months
• •Avoid: Repeated freeze-thaw cycles (degrades peptide)

Safety and Tolerability

Adverse Event Profile (from Clinical Literature)

Semax has been used clinically in Russia for over 25 years with an excellent safety record:

Common Side Effects (mild, transient):

• •Nasal irritation or congestion (5-10% of users) — typically resolves with continued use
• •Transient headache (2-5%) — usually within first 1-2 hours of dose
• •Mild nasal irritation or epistaxis (1-2%) — rare; resolves spontaneously

Serious Adverse Events: None reported in Russian clinical literature at therapeutic doses.

Hormonal Effects:

Despite being derived from ACTH, Semax does NOT cause:

• •Cortisol elevation (ACTH-like effect)
• •Glucocorticoid-related side effects
• •Hypothalamic-pituitary-adrenal axis dysregulation
• •Immunosuppression

This is because the ACTH(4-7) fragment lacks the N-terminal sequence required for corticotropin receptor (MC2R) activation.

Tolerability in Long-Term Use

Russian clinical experience suggests excellent tolerability with:

• •No tolerance development (no dose escalation needed over months of use)
• •No withdrawal effects upon discontinuation
• •No organ toxicity observed in patients using Semax for years
• •No significant drug interactions reported

Clinical Applications Beyond Stroke

Cognitive Decline and Dementia (Off-Label Research)

Preliminary data suggest potential roles in:

• •Age-related cognitive decline (mild cognitive impairment)
• •Alzheimer's disease (experimental; BDNF-enhancing potential)
• •Vascular dementia (synergistic with stroke prevention)

ADHD and Attention Disorders

Limited research suggests Semax may enhance sustained attention and executive function in ADHD patients, though large-scale Western trials are lacking.

Optic Neuropathy and Vision Protection

Russian researchers have explored Semax for age-related vision loss and optic nerve damage, with mixed results. Mechanism likely involves neuroprotection of retinal ganglion cells.

Anxiety and Mood Disorders

Off-label use in Russia suggests anxiolytic effects, though research is limited compared to GABAergic anxiolytics. May work through HPA axis modulation.

Frequently Asked Questions

Q: Is Semax FDA-approved?

A: No. Semax is not FDA-approved and is available primarily through Russian medical suppliers and international research chemical vendors. It is not approved for any indication in the United States or Europe.

Q: How does Semax cross the blood-brain barrier?

A: Intranasal delivery via olfactory epithelium and trigeminal nerve endings allows rapid CNS penetration without systemic absorption or BBB crossing. This is why intranasal is the preferred route.

Q: What is the mechanism of cognitive effects?

A: BDNF and NGF upregulation in hippocampus, prefrontal cortex, and basal forebrain. These neurotrophic factors support synaptic plasticity, neuronal survival, and enhanced learning capacity.

Q: What is the half-life of Semax?

A: Plasma half-life is 4-8 minutes (rapid enzymatic degradation). However, CNS residence time is 2-4 hours, and BDNF-mediated effects persist for 12-24+ hours due to gene induction (not parent-peptide persistence).

Q: Is Semax safe for long-term use?

A: Clinical experience in Russia over 25+ years suggests favorable tolerability. Formal Western safety trials are limited, but no serious adverse events have been reported at therapeutic doses. No tolerance development is observed.

Q: Can Semax be combined with other nootropics or medications?

A: Research is limited. Theoretically, combining Semax with other BDNF-enhancing agents (e.g., exercise, enriched environment) may have synergistic effects. No major drug interactions are known, but clinical data on combinations is sparse.

Q: What dosing is used in research?

A: Intranasal 5-10 mg once or twice daily is typical. Research protocols vary; animal studies use 0.5-2 mg/kg IP or SC. Always follow protocol specifications and animal care guidelines.

Conclusion

Semax represents a well-researched neuropeptide with substantial clinical data from Russian sources, supporting roles in acute stroke recovery and cognitive enhancement, likely mediated by BDNF and NGF upregulation. The peptide's unique mechanism (ACTH-fragment-derived but lacking glucocorticoid effects), excellent intranasal bioavailability, and three decades of clinical experience make it a valuable research tool for investigating neuroprotection and cognitive enhancement.

Future research priorities include large-scale Western clinical trials (particularly in acute stroke and cognitive impairment), mechanistic studies of BDNF upregulation pathways, and investigation of combination approaches with established neuroprotective therapies. The excellent safety profile and lack of tolerance development make Semax a promising avenue for long-term cognitive and neuroprotective research.

---

For research purposes only. Not for human use.